Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients

Sponsor
Egymedicalpedia
Study ID
NCT06370156
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Adalimumab — DRUG
    To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.

Study Details

Psoriasis vulgaris is associated with significant comorbidity including depression, increased risk of cardiovascular events, diminished quality of life, as well as overall increased mortality. Moreover, concomitant psoriatic arthritis is present in up to 40% of psoriasis patients or will develop in the future. To enhance quality of life and potentially lower the risk of concomitant disease in psoriasis patients, effective treatment of this immune-mediated systemic inflammatory disease is required

Key Dates

Start date
Jun 1, 2024
Status verified
Apr 2024
Primary completion
Jun 1, 2025
Completion
Jun 10, 2025

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Group A : (Adalimumab therapy)
    About 30 patients suffering from Plaque Psoriasis and will take Adalimumab therapy orally. Correlation between serum\& TWEAK levels and Psoriasis Area and Severity Index (PASI) score and the ACR score pre and post Adalimumab therapy
  • Arm: Group B : (methotrexate therapy)
    About 30 patients suffering from Psoriatic arthritis and will take methotrexate therapy orally. Correlation between serum\& TWEAK levels and Psoriasis Area and Severity Index (PASI) score and the ACR score pre and post methotrexate therapy
  • Arm: Group C: (control Group):
    About 40 healthy individuals selected as control group as related to age, sex ,BMI matching with healthy individuals

Primary Outcome Measure

Treatment of psoriasis vulgaris and psoriatic arthritis [ Time Frame: 1 year ]

Central Contacts

Related Studies